Case Report
Copyright ©The Author(s) 2025.
World J Clin Oncol. Mar 24, 2025; 16(3): 99527
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.99527
Figure 2
Figure 2 Computed tomography images. A: Evidence of liver metastatic disease after surgery (November 2023); B: Liver metastasis progression after FOLFIRI plus bevacizumab regimen (March 2024); C: Partial remission of liver metastases after disitamab vedotin-containing therapy (June 2024); D: Continuous remission of liver metastases after disitamab vedotin-containing therapy (September 2024).